Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
===================================================================================================================================================

* Biagio Ricciuti
* Greg Jones
* Mariano Severgnini
* Joao V Alessi
* Gonzalo Recondo
* Marissa Lawrence
* Tim Forshew
* Christine Lydon
* Mizuki Nishino
* Michael Cheng
* Mark Awad